We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about MorphoSys.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

13/01/2020
MorphoSys and Incyte Sign Global Collaboration and License Agreement for...
13/01/2020
MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and...
30/12/2019
MorphoSys Announces Submission of Biologics License Application for...
27/12/2019
First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline...
12/12/2019
MorphoSys AG: Corporate Calendar 2020
20/11/2019
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His...
18/11/2019
MorphoSys' tafasitamab B-MIND DLBCL study successfully passed...
18/11/2019
Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed...
15/11/2019
MorphoSys Continues to Build Commercial Presence by Opening new U.S....
11/11/2019
Results for Bimagrumab in Obesity and Type 2 Diabetes presented by...

January 15, 2020
Webcast
38th Annual J.P. Morgan Healthcare Conference
San Francisco, CA, USA

Full details